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Abstract C215: Sensitivity of PTEN-
deficient prostate carcinoma xenografts to 
ionizing radiation through inhibition of 
treatment-induced CXCL8 signaling. 
Chris WD Armstrong, Jonathan A. Coulter, Steven Walker, Richard D. Kennedy, Kevin M. 
Prise, Joe M. O'Sullivan and David JJ Waugh 
Abstract 
Background: CXCL8 signaling levels are elevated in localized high grade prostate cancer 
(CaP). We have shown exposure of CaP cells to chemical DNA-damaging agents potentiates 
CXCL8 signaling, which underpins an autocrine mode of therapeutic resistance. Data from in 
vitro and in vivo CaP models has shown loss of the tumor suppressor PTEN also increases 
expression of the pro-inflammatory chemokine CXCL8. Experiments were designed to 
determine whether exposure to ionising radiation (IR) selectively induced CXC-chemokine 
signaling in PTEN-deficient CaP cells, and to determine how CXCL8 signaling may 
modulate their radiosensitivity. 
Methods: shRNA-directed strategies were used to establish cell-based models of CaP with 
differential expression of PTEN. These clonal (DU145) and heterogeneous (22Rv1) 
populations were subjected to IR under normal or hypoxic culture conditions. PTEN was 
reconstituted in PC3 cells and was driven by tetracycline-regulated expression of the gene. 
Changes in chemokine expression were analyzed by RT-PCR, immunoblotting and ELISA. 
Autocrine CXCL8 signaling was attenuated using siRNA to down-regulate gene expression 
of its receptors, CXCR1 and CXCR2. The effects of modulating chemokine signaling on cell 
viability following exposure to clinically-relevant doses of IR were assessed by colony 
formation assays, cell proliferation assays, and analysis of apoptosis and cellular senescence. 
The effect of CXCL8 signaling inhibition in vivo was determined using a PC3 xenograft 
model in SCID mice. The cell penetrating pepducin, x1/2pal-i3, was used to attenuate both 
CXCR1 and CXCR2 and tumor growth was assessed via caliper measurements. 
Results: Exposure to IR (3 Gy) increased gene expression of CXCL8, CXCR1 and CXCR2 - 
with PTEN-deficiency enhancing this response. Loss of PTEN expression differentially 
modulated the radiosensitivty of CaP cell lines: PTEN-depletion conferred relative 
radioresistance in DU145 cells but made 22RV1 cells more radiosensitive. However, the 
inhibition of CXCL8 signaling in all PTEN-depleted models resulted in consistently 
increased radiosensitivity (SER 1.2, 1.13, and 1.39 in DU145, 22RV1, and PC3 CaP cells, 
respectively; p<0.05). Reconstitution of PTEN expression in PC3 cells abrogated the capacity 
of CXCL8 signaling blockade to confer radiosensitivity. The combination of IR and CXCL8 
signaling-inhibition conferred increased apoptosis in DU145 cells (p53 mutant) but induced 
premature senescence in 22RV1 cells (p53 WT). In vivo, treatment of PC3 xenografts with 
x1/2pal-i3 combined with IR (3 Gy) resulted in a significant delay in tumor growth compared 
to control (median quadrupling time: 42 day x1/2pal-i3 & IR vs. 32 day control & IR; 
p<0.05). Subsequent analysis of gene expression in these tumors confirmed that CXCL8 
signaling inhibition attenuated IR-induced expression of anti-apoptotic proteins Bcl-2 and C-
FLIP. 
Conclusions: Our results demonstrate the role of treatment-induced CXCL8 signaling as a 
mechanism of resistance to IR in PTEN-depleted CaP cells. Inhibition of IR-induced CXCL8 
signaling provides a novel therapeutic opportunity to enhance the radiosensitivity of PTEN-
depleted CaP cells. However, mechanistic results indicate that other genetic factors including 
p53 status dictate the resultant induction of treatment-induced apoptosis. 
 
